Acorda Therapeutics, Inc.

NASDAQ: ACOR
$0.73
-$0.03 (-4.5%)
Real time price as of July 16, 2020 12:55 pm EDT
Thursday's top analyst upgrades, downgrades and initiations included BankUnited, Caterpillar, Costco, eBay, Ford, Kellogg, Lyft, Microsoft and Oshkosh.
The top analyst upgrades, downgrades and initiations for Wednesday included Acorda Therapeutics, Activision Blizzard, Bloom Energy, Care.com, CBS, Deere and Ferrari.
The top analyst upgrades, downgrades and initiations seen on Friday included Carbonite, Cleveland-Cliffs, Conoco, Costco, EA, Eli Lilly, HP, PepsiCo and Roku.
Acorda Therapeutics shares dipped on Thursday after the company announced that the FDA would be delaying its Prescription Drug User Fee Act goal date for its review of the New Drug Application of...
The top analyst upgrades, downgrades and other research calls from Friday include Alarm.com, Biogen, Blue Apron, Cisco, Lowe's, Pandora Media and Waste Management.
Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two weeks to start the year.
The top analyst upgrades, downgrades and other research calls from Thursday include Cisco Systems, Dollar General, NetApp, Pandora Media, Procter & Gamble and Target.
Acorda Therapeutics saw its shares drop sharply following an announcement that it had paused new enrollment in a long-term safety study. In a sense, Acorda has halted this trial.
The top analyst upgrades, downgrades and other research calls from Wednesday include Equifax, Mallinckrodt, Nabors, Qualcomm, Salesforce and Snap.
Acorda Therapeutics saw its shares get crushed early on Tuesday after the firm received a Refusal to File letter from the FDA in regards to its New Drug Application for Inbrija.
The top analyst upgrades, downgrades and initiations seen on Monday include AIG, Boeing, GameStop, Gilead Sciences, Starbucks, CIGNA, Ciena and Ferrari.
The top analyst upgrades, downgrades and initiations seen on Wednesday include BBVA, Fossil, Procter & Gamble, T-Mobile, Under Armour and Universal Display.
Shares of Acorda Therapeutics saw a hand gain in early trading on Thursday after the company reported results from its late-stage Parkinson’s trial.
Monday’s top analyst upgrades, downgrades and initiations include Anadarko Petroleum, Bristol-Myers Squibb, Comcast, Walt Disney and Merck.
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is watching its shares slide on Monday after the company gave an update on a recent clinical study. Essentially, the company announced that its Milestone...